keyword
https://read.qxmd.com/read/38527841/-single-non-blood-related-umbilical-cord-blood-transplantation-using-a-reduced-intensity-conditioning-regimen-for-the-treatment-of-severe-aplastic-anemia
#1
JOURNAL ARTICLE
Y Wu, B L Tang, K D Song, G Y Sun, T Z Pan, A J Huang, B B Yan, X Y Zhu
Objective: To evaluated the clinical efficacy of a reduced-intensity preconditioning regimen for single non-blood-related umbilical cord blood transplantation (sUCBT) in the treatment of severe aplastic anemia (SAA) . Methods: The clinical data of 63 patients with SAA who underwent sUCBT from January 2021 to July 2023 at the Department of Hematology of the First Affiliated Hospital of USTC were retrospectively analyzed. Fifty-two patients received total body irradiation/total bone marrow irradiation (TMI) combined with fludarabine or a cyclophosphamide- conditioning regimen (non-rATG group) , while 11 patients received rabbit anti-human thymocyte immunoglobulin (rATG) combined with TMI, fludarabine, or the cyclophosphamide-conditioning regimen (rATG group) ...
January 14, 2024: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://read.qxmd.com/read/38522856/severe-liver-dysfunction-after-donor-lymphocyte-infusion-for-relapsed-multiple-myeloma
#2
Tae-Hoon No, Nae-Yun Heo, Seung Ha Park, Joon Hyuk Choi, Junghwan Lee, Sung Nam Lim, Seon Yang Park
Donor lymphocyte infusion (DLI) is performed to augment an anti-tumor immune response or ensure donor stem cells remain engrafted following allogeneic stem cell transplantation but may induce graft-versus-host disease (GVHD) involving skin, intestine, and liver. Although hepatic involvement of GVHD can manifest as mild to severe hepatitis, few reports have mentioned acute severe liver dysfunction with encephalopathy. We experienced a case of acute severe liver dysfunction with semicoma after DLI in a patient with relapsed multiple myeloma following allogeneic stem cell transplantation, in whom chronic viral hepatitis B had been suppressed by antiviral treatment...
March 25, 2024: Korean Journal of Gastroenterology, Taehan Sohwagi Hakhoe Chi
https://read.qxmd.com/read/38511425/transplant-versus-no-transplant-in-myelodysplastic-syndrome-and-acute-myeloid-leukemia-with-tp53-mutation-a-referral-center-experience
#3
JOURNAL ARTICLE
Kittika Poonsombudlert, Sarah Mott, Benda Miller, Prajwal Dhakal, Anthony Snow, Sarah Hornberg, Ratdanai Yodsuwan, Christopher Strouse, Hira Shaikh, Margarida Magalhaes-Silverman, Grerk Sutamtewagul
A remarkably high rate of post-transplant relapse in patients with TP53-mutated myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) calls to question the utility of allogeneic stem cell transplant (HSCT). We, therefore, performed a retrospective analysis to compare the outcomes between HSCT (N = 38) versus non-HSCT (N = 45) approaches. Patients in the HSCT cohort were younger (median age 63 vs. 72) while patients in the non-HSCT cohort more commonly had complex karyotype with chromosome 17 aberrancy and 5q deletion (p < ...
March 21, 2024: European Journal of Haematology
https://read.qxmd.com/read/38503942/allogeneic-hematopoietic-stem-cell-transplantation-for-patients-with-richter-transformation-a-retrospective-study-on-behalf-of-the-chronic-malignancies-working-party-of-the-ebmt
#4
JOURNAL ARTICLE
Romain Guièze, Diderik-Jan Eikema, Linda Koster, Johannes Schetelig, Henrik Sengeloev, Jakob Passweg, Jürgen Finke, Mutlu Arat, Annoek E C Broers, Friedrich Stölzel, Jenny Byrne, Cristina Castilla-Llorente, Peter Dreger, Matthias Eder, Tobias Gedde-Dahl, Nicolaus Kröger, Josep Maria Ribera Santasusana, Deborah Richardson, Alessandro Rambaldi, Lucrecia Yañez, Michel Van Gelder, Joanna Drozd-Sokolowska, Kavita Raj, Ibrahim Yakoub-Agha, Olivier Tournilhac, Donal P McLornan
Management of Richter transformation (RT) is particularly challenging, with survival estimates <1 year. We report on outcomes of 66 RT patients undergoing allogeneic-HCT (allo-HCT) between 2008 and 2018 registered with the EBMT. Median age at allo-HCT was 56.2 years (interquartile range (IQR), 51.3-63.1). Median time from RT to allo-HCT was 6.9 months (IQR, 4.9-11) and 28 (42.4%) were in complete remission (CR). The majority underwent reduced intensity conditioning (66.2%) using peripheral blood derived stem cells...
March 19, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38501153/clinical-pharmacology-considerations-for-the-off-the-shelf-allogeneic-cell-therapies
#5
REVIEW
Hardik Mody, Dhruvitkumar S Sutaria, Dale Miles
Autologous chimeric antigen receptor T-cell (CAR-T) therapies have garnered unprecedented clinical success with multiple regulatory approvals for the treatment of various hematological malignancies. However, there are still several clinical challenges that limit their broad utilization for aggressive disease conditions. To address some of these challenges, allogeneic cell therapies are evaluated as an alternative approach. As compared with autologous products, they offer several advantages, such as a more standardized "off the shelf" product, reduced manufacturing complexity, and no requirement of bridging therapy...
March 19, 2024: Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/38499288/cellular-senescence-promotes-meibomian-gland-dysfunction-in-a-chronic-graft-versus-host-disease-mouse-model
#6
JOURNAL ARTICLE
Shinri Sato, Yoko Ogawa, Eisuke Shimizu, Kazuki Asai, Takahiro Okazaki, Robert Rusch, Masatoshi Hirayama, Shigeto Shimmura, Kazuno Negishi, Kazuo Tsubota
PURPOSE: Aging is a well-established risk factor for meibomian gland dysfunction (MGD). We previously reported an accelerated cellular senescence phenomenon in the lacrimal glands of a murine model of chronic graft-versus-host disease (cGVHD). Herein, we aimed to elucidate the relationship between cellular senescence and MGD in cGVHD mice, utilizing the senolytic agent ABT-263. METHODS: A cGVHD mouse model was established through allogeneic bone marrow transplantation (BMT) from B10...
March 16, 2024: Ocular Surface
https://read.qxmd.com/read/38499070/fecal-microbiota-transplant-on-escherichia-shigella-gut-composition-and-its-potential-role-in-the-treatment-of-generalized-anxiety-disorder-a-systematic-review
#7
REVIEW
Meghan M Baske, Kiara C Timmerman, Lucas G Garmo, Megan N Freitas, Katherine A McCollum, Tom Y Ren
BACKGROUND: The gut-brain-axis has a role in mental health disorders. In people with generalized anxiety disorder, GAD,1 normal flora Escherichia-Shigella, are significantly elevated. Fecal microbiota transplant, FMT,2 has been used to alter the gut composition in unhealthy individuals. There may be a role for FMT in the treatment of GAD to improve the gut-brain-axis. METHODS: A systematic review of literature was conducted on articles published in PubMed, CINAHL Plus, Scopus, Cochrane Library, and Wed of Science from 2000 to 2022 that analyzed FMT as a modality to alter the gut microbiome in which Escherichia-Shigella levels were quantified and reported...
March 16, 2024: Journal of Affective Disorders
https://read.qxmd.com/read/38485723/ptcy-versus-atg-as-graft-versus-host-disease-prophylaxis-in-mismatched-unrelated-stem-cell-transplantation
#8
JOURNAL ARTICLE
Olaf Penack, Mouad Abouqateb, Christophe Peczynski, William Boreland, Zafer Gülbas, Tobias Gedde-Dahl, Cristina Castilla-Llorente, Nicolaus Kröger, Mathias Eder, Alessandro Rambaldi, Francesca Bonifazi, Igor Wolfgang Blau, Matthias Stelljes, Peter Dreger, Ivan Moiseev, Hélène Schoemans, Christian Koenecke, Zinaida Peric
There is an increased risk of GVHD and of non-relapse mortality (NRM) after allogeneic stem cell transplantations (alloSCT) when mismatched unrelated donors (MMUD) are used. In Europe, it is standard practice to use rabbit anti-thymocyte globulin (rATG) to reduce the high NRM and GVHD risks after MMUD alloSCT. As an alternative to rATG, post-transplantation Cyclophosphamide (PTCy) is in increasing clinical use. It is currently impossible to give general recommendations regarding preference for one method over another since comparative evidence from larger data sets is lacking...
March 15, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38479549/treatment-sensitive-and-treatment-dependent-chronic-gvhd-yield-superior-failure-free-and-overall-survival-compared-to-treatment-resistant-chronic-gvhd
#9
JOURNAL ARTICLE
Najla El Jurdi, Shannon Herzog, Ryan Shanley, Shernan G Holtan, Margaret L MacMillan, Daniel J Weisdorf
BACKGROUND: Response to chronic graft-versus-host disease (cGVHD) treatment may help predict prognosis and outcomes. We hypothesized that cGVHD response to treatment and ability to taper immunosuppression defines distinct treatment response categories that differ in risk factors and prognosis. OBJECTIVE: Our aim was to determine specific clinical characteristics and outcomes associated with 3 distinct cGVHD treatment response groups based on response and duration of immune suppression therapy (IST) as: treatment sensitive (TS), resistant (TR) and treatment dependent (TD) cGVHD...
March 11, 2024: Transplantation and cellular therapy
https://read.qxmd.com/read/38469371/a-case-of-successful-allogeneic-hematopoietic-stem-cell-transplantation-in-a-severely-underweight-patient-with-aplastic-anemia
#10
Lilija Banceviča, Andrius Žučenka
Allogeneic hematopoietic stem cell transplantation (alloHSTC) is considered definitive and the most effective treatment for young patients diagnosed with severe aplastic anemia. Low body mass index (BMI) is known to be associated with poorer outcomes in stem cell transplantation and higher mortality risks. Malnutrition negatively affects the patient's ability to mobilize stem cells, therefore reducing patients' stem cell production, although the patient's nutritional status improvement with enteral and parenteral nutrition may reduce the risks of stem cell graft failure and graft-vs-host disease (GVHD) occurrence...
2024: Case Reports in Hematology
https://read.qxmd.com/read/38467719/effective-treatment-of-clostridioides-difficile-infection-improves-survival-and-affects-graft-versus-host-disease-a-multicenter-study-by-the-polish-adult-leukemia-group
#11
JOURNAL ARTICLE
Agnieszka Piekarska, Alicja Sadowska-Klasa, Patrycja Mensah-Glanowska, Małgorzata Sobczyk-Kruszelnicka, Joanna Drozd-Sokołowska, Anna Waszczuk-Gajda, Joanna Kujawska, Mateusz Wilk, Agnieszka Tomaszewska, Jan M Zaucha, Sebastian Giebel, Lidia Gil
Clostridioides difficile infection (CDI) is the most common cause of infectious diarrhea after allogeneic hematopoietic cell transplantation (allo-HCT). The impact of CDI and its treatment on allo-HCT outcomes and graft-versus-host disease (GVHD), including gastrointestinal GVHD (GI-GVHD) is not well established. This multicenter study assessed real-life data on the first-line treatment of CDI and its impact on allo-HCT outcomes. Retrospective and prospective data of patients with CDI after allo-HCT were assessed...
March 11, 2024: Scientific Reports
https://read.qxmd.com/read/38467032/combined-effect-of-unrelated-donor-age-and-hla-peptide-binding-motifs-pbm-match-status-on-hct-outcomes
#12
JOURNAL ARTICLE
Rohtesh S Mehta, Effie W Petersdorf, Stephen R Spellman, Stephanie J Lee
An HLA-mismatched unrelated donor (MMUD) who is class I protein binding motifs (PBM)-matched is preferred over a PBM-mismatched donor. We hypothesized that using a younger donor (<35 years vs >35 years) could compensate for the inferior overall survival (OS) associated with PBM-mismatches. We compared six groups: HLA-matched/younger donor (n=10,531), HLA-matched/older donor (n=3572), PBM-matched/younger donor (n=357), PBM-matched/older donor (n=257), PBM-mismatched/younger donor (n=616), and PBM-mismatched/older donor (n=339) in patients undergoing transplantation with conventional graft-versus-host disease (GVHD) prophylaxis...
March 11, 2024: Blood Advances
https://read.qxmd.com/read/38462861/outcomes-of-haematopoietic-stem-cell-transplantation-in-beta-thalassemia-major-with-fully-matched-parents-as-donor
#13
JOURNAL ARTICLE
Asghar Ali Kerio, Nighat Shahbaz, Tariq Azam Khattak, Tariq Ghafoor, Muhammad Farhan, Hashim Khan
OBJECTIVE: To determine the outcome of beta thalassemia major (BTM) patients undergoing haematopoietic stem cells (HSCT), with fully matched parents as donors vs. matched sibling donors (MSD). STUDY DESIGN: Observational Study. Place and Duration of the Study: Department of Clinical Haematology and Bone Marrow Transplantation Centre, Rawalpindi, Pakistan, from January 2013 to July 2023. METHODOLOGY: Group A consisted of BTM patients who underwent HSCT with fully matched siblings as donors, and Group B consisted of BTM patients who underwent HSCT with fully matched parents as donors...
March 2024: Journal of the College of Physicians and Surgeons—Pakistan: JCPSP
https://read.qxmd.com/read/38462215/pre-transplant-blinatumomab-improves-outcomes-in-b-cell-acute-lymphoblastic-leukemia-patients-who-undergo-allogeneic-hematopoietic-cell-transplantation
#14
JOURNAL ARTICLE
Ayman Sayyed, Carol Chen, Armin Gerbitz, Dennis Dong Hwan Kim, Rajat Kumar, Wilson Lam, Arjun Datt Law, Jeffrey H Lipton, Fotios V Michelis, Igor Novitzky-Basso, Auro Viswabandya, Jonas Mattsson, Ivan Pasic
BACKGROUND: Blinatumomab, a bispecific monoclonal antibody, effectively controls refractory B-cell acute lymphoblastic leukemia (ALL) and promotes measurable residual disease (MRD) negativity. This study investigated the impact of pre-transplant blinatumomab on allogeneic hematopoietic cell transplantation (HCT) outcomes in B-cell ALL patients. METHODS: We analyzed the effect of pre-transplant blinatumomab on transplant outcomes of 117 adults undergoing allogeneic HCT for B-cell ALL at Princess Margaret Hospital, Toronto, between 2010 and 2021...
March 8, 2024: Transplantation and cellular therapy
https://read.qxmd.com/read/38458479/long-term-clinical-outcomes-and-b-cell-immune-reconstitution-following-allo-hct-with-prophylactic-post-transplant-rituximab
#15
JOURNAL ARTICLE
Vanessa E Kennedy, Bita Sahaf, Fang Wu, Zachary J Ehlinger, Sally Arai, David B Miklos
BACKGROUND: Chronic graft-versus-host disease (cGVHD) remains a significant source of morbidity and mortality following allogeneic hematopoietic cell transplantation (HCT). Post-transplant, prophylactic rituximab has successfully decreased cGHVD rates in clinical trials, but the durability of this strategy is uncertain. The long-terms effect of post-HCT B cell depletion on immune reconstitution, B cell function, and infectious complications are also unknown. OBJECTIVE: In this study, we provide 10 year follow-up and correlative analyses on patients given post-HCT, prophylactic rituximab...
March 6, 2024: Transplantation and cellular therapy
https://read.qxmd.com/read/38458476/gut-immunomodulation-with-vedolizumab-prior-to-allogeneic-hematopoietic-stem-cell-transplantation-in-pediatric-patients-with-inflammatory-bowel-disease
#16
JOURNAL ARTICLE
Yogi Chopra, Karol Acevedo, Aleixo Muise, Karen Frost, Tal Schechter, Joerg Krueger, Muhammad Ali, Kuang-Yueh Chiang, V Y Kim, Eyal Grunebaum, Donna Wall
BACKGROUND: Inborn errors of immunity (IEI) are often associated with inflammatory bowel disease (IBD). IEI can be corrected by allogeneic hematopoietic stem cell transplantation (HSCT) however peri-transplantation intestinal inflammation may lead to increased risk of gut graft-versus-host disease (GVHD). Vedolizumab inhibits the homing of lymphocytes to the intestine and may attenuate gut GVHD, yet its role in preventing GvHD in pediatric patients with IEI-associated IBD has not been studied...
March 6, 2024: Transplantation and cellular therapy
https://read.qxmd.com/read/38454927/determining-the-predictive-impact-of-donor-parity-on-the-outcomes-of-human-leukocyte-antigen-matched-hematopoietic-stem-cell-transplants-a-retrospective-single-center-study
#17
JOURNAL ARTICLE
Mojtaba Azari, Maryam Barkhordar, Tanaz Bahri, Soroush Rad, Hosein Kamranzadeh Fumani, Seied Asadollah Mousavi, Sahar Tavakoli Shiraji, Morteza Azari, Parisa Shafaroudi, Mohammad Vaezi
INTRODUCTION: Donor choosing remains to play a pivotal role in allogeneic hematopoietic stem cell transplantation (allo-HSCT). Numerous criteria beyond HLA compatibility impact the selection of a suitable donor. METHODS: We evaluated the effect of donor parity on transplant outcomes in a large homogeneously treated population that received an HLA-matched allo-HSCT between 2010 and 2021 at our center. All patients were transplanted from a peripheral blood stem cell source following a myeloablative Busulfan-based conditioning and an identical protocol for graftversus-host disease (GVHD) prophylaxis regimen...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38450530/cell-free-dna-from-nail-clippings-as-source-of-normal-control-for-genomic-studies-in-hematologic-malignancies
#18
JOURNAL ARTICLE
Melissa Krystel-Whittemore, Kseniya Petrova-Drus, Ryan N Ptashkin, Mark D Ewalt, JinJuan Yao, Ying Liu, Menglei Zhu, Jamal Benhamida, Benjamin Durham, Jyoti Kumar, Khedoudja Nafa, Iwona Kiecka, Anita S Bowman, Erika Gedvilaite, Jacklyn Casanova, Yun-Te Lin, Abhinita S Mohanty, Satshil Rana, Anoop Balakrishnan Rema, Ivelise Rijo, Nelio Chaves, Paulo Salazar, Anita Yun, Sean Lachhander, Wei Wang, Mohammad S Haque, Wenbin Xiao, Mikhail Roshal, Sergio Giralt, Gilles Salles, Raajit Rampal, Eytan M Stein, Miguel-Angel Perales, Steven Horwitz, Ann Jakubowski, Doris Ponce, Alina Markova, Ozge Birsoy, Diana Mandelker, Simon Mantha, Ahmet Dogan, Ryma Benayed, Marc Ladanyi, Michael F Berger, A Rose Brannon, Ahmet Zehir, Chad Vanderbilt, Maria E Arcila
Comprehensive genomic sequencing is becoming a critical component in the assessment of hematologic malignancies, with broad implications for patient management. In this context, unequivocally discriminating somatic from germline events is challenging but greatly facilitated by matched analysis of tumor:normal pairs. In contrast to solid tumors, conventional sources of normal control (peripheral blood, buccal swabs, saliva) could be highly involved by the neoplastic process, rendering them unsuitable. In this work we describe our real-world experience using cell free DNA (cfDNA) isolated from nail clippings as an alternate source of normal control, through the dedicated review of 2,610 tumor:nail pairs comprehensively sequenced by MSK-IMPACT-heme...
March 7, 2024: Haematologica
https://read.qxmd.com/read/38447750/recombinant-human-thrombopoietin-promotes-platelet-engraftment-in-severe-aplastic-anemia-patients-following-treatment-with-haploid-hematopoietic-stem-cell-transplantation-using-modified-post-transplantation-cyclophosphamide
#19
JOURNAL ARTICLE
Andie Fu, Yizhou Peng, Ping Cheng, Jiaying Wu, Xiaojian Zhu, Yang Yang, Lifang Huang, Na Wang, Jue Wang, Jinhuan Xu, Yuling Wan, Yang Cao, Jia Wei, Yi Xiao, Fankai Meng, Hui Cheng, Yicheng Zhang, Donghua Zhang
BACKGROUND: Recombinant human TPO (rhTPO) promotes platelet engraftment in patients after allogeneic HSCT (allo-HSCT). However, the effects of rhTPO on platelet recovery after Haplo-HSCT in patients with severe aplastic anemia (SAA) have not been intensively studied. OBJECTIVE: We aimed to evaluate the efficacy of rhTPO on platelet engraftment in patients with SAA who were treated with Haplo-HSCT using post-transplantation cyclophosphamide (PTCy). STUDY DESIGN: SAA patients who received Haplo-HSCT plus PTCy regimen were divided into the rhTPO group (with subcutaneous injection of rhTPO, n=28) and Control group (no rhTPO administration, n=27)...
March 4, 2024: Transplantation and cellular therapy
https://read.qxmd.com/read/38431738/exploring-strategies-to-optimise-outcomes-in-hepatitis-associated-aplastic-anaemia-patients-following-haematopoietic-stem-cell-transplantation
#20
JOURNAL ARTICLE
Jia Li, Yilin Liu, Jieru Wang, Yan Wang, Aiming Pang, Donglin Yang, Xin Chen, Rongli Zhang, Jialin Wei, Qiaoling Ma, Weihua Zhai, Yi He, Erlie Jiang, Mingzhe Han, Sizhou Feng
This study aimed to assess haematopoietic stem cell transplantation (HSCT) safety and efficacy while exploring strategies for optimising outcomes in patients with hepatitis-associated aplastic anaemia (HAAA). We retrospectively reviewed 35 HAAA patients who underwent HSCT at a large Chinese blood disease hospital between 2008 and 2022. HAAA patients receiving HSCT typically presented with severe (28.6%) and very severe (65.7%) AA. Male patients predominated (68.6%), with a median onset age of 23 years (range, 9-44)...
March 2, 2024: Scientific Reports
keyword
keyword
13944
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.